Guidance

PCV risk groups: patient group direction template

Patient group direction (PGD) template to support the provision of PCV13 vaccine to individuals with underlying medical conditions.

Document

PCV risk groups: PGD template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD template supports the provision of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13) to individuals with underlying medical conditions. It is valid from 1 June 2017 to 31 May 2019.

The template requires further authorisation by an appropriate authorising person, relating to the class of person by whom product is to be supplied, in accordance with the Human Medicines Regulations 2012 (HMR). This may be a clinical governance or patient safety lead, who has designated responsibility for signing PGDs on behalf of the authorising body. The PGD is not legal or valid without signed authorisation in accordance with HMR 2012 schedule 16 part 2.

Adoption and governance of the use of this PGD is the responsibility of the authorising organisation and provider.

Provider organisations, health professionals and immunisation practitioners should check they are working to the current PGD versions and only work to documents authorised in accordance with HMR 2012 schedule 16 part 2.

These PGDs should be used with reference to the Green Book, and Summary of Product Characteristics for the vaccine.

Published 1 March 2017
Last updated 26 May 2017 + show all updates
  1. Version 2. Updated PGD dose section in line with revised pneumococcal Green Book chapter and refined inclusion criteria.
  2. First published.